Article Author:
Associated Press
BERLIN (AP) — BioNTech, which collaborated with Pfizer to develop the first widely-used COVID-19 vaccine, reports increased revenue and net profit for the first half of the year, with the release of We anticipate that demand will increase as a result. Updated vaccine to target new Omicron strains.
The German pharmaceutical company said on Monday that it had reached about €9.57 billion ($9.76 billion) in sales in its first six months of 2022, up from about €7.36 billion in the same period last year. Announced. However, sales fell from 5.31 billion euros in the April-June period last year to around 3.2 billion euros in the second quarter.
BioNTech said the dynamic nature of the pandemic had caused changes in orders and earnings, but expected a strong end to the year. The company says it plans to release an improved vaccine tailored to the latest Omicron variant as early as October, which could lead to a fall booster campaign.
"With his initiative on a variant-adapted COVID-19 vaccine candidate, we expect demand to increase in key markets in the fourth quarter of 2022, subject to regulatory approval." He said Jens Holstein. BioNTech said in his release to the press.
Moderna, another of his leading COVID-19 vaccine makers, is also working on an updated version of Shot to release this fall.
BioNTech is expected to report revenues of €17 billion from his €13 billion from COVID-19 vaccines this year.
Net profits for German companies were also higher in the first half of 2021, at €5.37bn vs. €3.92bn, and lower in the second quarter, at €1.67bn vs. €2.79bn. Euro.
For partner Pfizer, his COVID-19 vaccine and therapeutics sales in the second quarter pushed the pharmaceutical giant to its biggest quarterly sales ever. The company said last month it made $9.9 billion from April to June.
